{"id":"W4281636766","doi":"10.1182/bloodadvances.2021006193","title":"Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma","year":2022,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal; McMaster University","funders":"Kite Pharma; Chugai Pharmaceutical; Genentech; MorphoSys; SymBio Pharmaceuticals Limited; Ono Pharmaceutical; Teijin Pharma; TG Therapeutics; Kiadis Pharma; Japan Science and Technology Agency; Juno Therapeutics; Astellas Pharma; Eisai; Daiichi-Sankyo; Omeros Corporation; Pfizer; Incyte; BeiGene; Loxo Oncology; Astex Pharmaceuticals; Nippon Shinyaku; Regeneron Pharmaceuticals; Bristol-Myers Squibb; AstraZeneca; CSL Behring; Karyopharm Therapeutics; Atara Biotherapeutics; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Sanofi; Celgene; Amgen; Fuji Pharma; Japan Society for the Promotion of Science; GlaxoSmithKline","keywords":"Diffuse large B-cell lymphoma; Refractory (planetary science); Lymphoma; Medicine; Term (time); Oncology; Internal medicine; Cancer research; Biology; Physics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005614656,0.0002180779,0.0007785815,0.0001461657,0.000229906,0.0005361019,0.0002947834,0.0003719993,0.002649087],"category_scores_gemma":[0.0008770892,0.00007285628,0.0006889845,0.0002162707,0.0002171395,0.0004103745,0.0001709976,0.001471276,0.0006919542],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000406777,"about_ca_system_score_gemma":0.0003816765,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003309711,"about_ca_topic_score_gemma":0.0009343066,"domain_scores_codex":[0.9997876,0.00008795503,0.00001386102,0.00002730219,0.00003290202,0.00005036254],"domain_scores_gemma":[0.9995486,0.000143948,0.0001161957,0.00004337633,0.00004534059,0.0001024609],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.1423197,0.002975687,0.0434302,0.001697639,0.002476871,0.0009105818,0.0002898222,0.001817695,0.0300974,0.0008491292,0.01011531,0.7630199],"study_design_scores_gemma":[0.08167632,0.3265707,0.4029454,0.001247883,0.00602824,0.009821385,0.0008282955,0.009010178,0.02622208,0.003543508,0.1319391,0.0001669251],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9569823,0.03136614,0.001407739,0.001558654,0.0002945172,0.0001437987,0.001862456,0.0001854583,0.00619887],"genre_scores_gemma":[0.9933107,0.002640187,0.0002154398,0.0007940355,0.0001171937,0.00006650834,0.001202315,0.00001929782,0.001634364],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002649087,"threshold_uncertainty_score":0.008862138,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009813489538978077,"score_gpt":0.2651330121369403,"score_spread":0.2553195225979622,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}